SCHEMBL4210049

SCHEMBL4210049

COC(=O)c1ccc(C(C)CC(=O)O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.53
TSHR P16473 1/20 0.50
POLB P06746 1/20 0.49
MAPT P10636 4/20 0.49
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA12 O43570 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.47
RAB9A P51151 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
GRIA4 P48058 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707578 0.92 FFAR1 (0.47) FFAR1TSHRPOLBMAPTCA1
SCHEMBL22337564 0.83 MAPT (0.46) TSHRMAPTCA1CA2TDP1
SCHEMBL5068158 0.83 CA12 (0.54) FFAR1MAPTCA1CA2TDP1
SCHEMBL29406165 0.83 ACHE (0.63) TSHRMAPTCA1CA2TDP1
SCHEMBL13713729 0.83 ACHE (0.63) TSHRMAPTCA1CA2TDP1
SCHEMBL277185 0.83 TSHR (0.50) TSHRPOLBMAPTCA1CA2
SCHEMBL16684851 0.82 L3MBTL1 (0.52) TSHRMAPTCA1CA2TDP1
SCHEMBL1791209 0.82 L3MBTL1 (0.52) TSHRMAPTCA1CA2TDP1
SCHEMBL14966780 0.82 CA1 (0.52) TSHRPOLBMAPTCA1CA2
SCHEMBL31037713 0.82 FFAR1 (0.49) FFAR1TSHRCA1CA2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012125-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them CAGE PETER 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012125-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them CCR3, CCR1, CCR5 FFAR1 1500/4885TSHR 4140/4885POLB 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.